These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22227647)

  • 1. EU court gets tough on patent extensions for combo products.
    Waters H
    Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647
    [No Abstract]   [Full Text] [Related]  

  • 2. The application of the patent laws to the drug approval process.
    Coggio BD; Cerrito FD
    Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
    [No Abstract]   [Full Text] [Related]  

  • 3. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 4. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
    Manthei JR; Hathaway CR; Grant MA; Chung DD
    Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032
    [No Abstract]   [Full Text] [Related]  

  • 5. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 6. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 7. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 8. A cheat sheet to navigate the complex maze of exclusivities in the United States.
    Peng B; Tomas MC
    Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
    [No Abstract]   [Full Text] [Related]  

  • 9. Preparing effective experimental data for pharmaceutical patent applications from US and Japanese perspectives.
    Altman D; Sweeney C; Yasui T
    Pharm Pat Anal; 2014 Sep; 3(5):469-73. PubMed ID: 25374314
    [No Abstract]   [Full Text] [Related]  

  • 10. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
    Eccleston LE
    Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
    [No Abstract]   [Full Text] [Related]  

  • 11. The need for balancing the regulation of pharmaceutical trademarks between the Food and Drug Administration and the Patent and Trademark Office.
    Boring D; Doninger C
    Food Drug Law J; 1997; 52(1):109-16. PubMed ID: 10346714
    [No Abstract]   [Full Text] [Related]  

  • 12. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 13. Bilski blundering biotech.
    Simmons WJ
    Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
    [No Abstract]   [Full Text] [Related]  

  • 14. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A
    Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent protection for medical technologies: why some and not others?
    Melzer D
    Lancet; 1998 Feb; 351(9101):518-9. PubMed ID: 9482467
    [No Abstract]   [Full Text] [Related]  

  • 16. U.S. patent law. Case probes what's fair game in the search for new drugs.
    Kintisch E
    Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
    [No Abstract]   [Full Text] [Related]  

  • 17. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
    [No Abstract]   [Full Text] [Related]  

  • 18. Patent battle lines drawn as sofosbuvir gains approval.
    Harrison C
    Nat Rev Drug Discov; 2014 Jan; 13(1):12. PubMed ID: 24378791
    [No Abstract]   [Full Text] [Related]  

  • 19. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 20. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.